EichorEICHOR
Condition: System Lupus Erythematosus Synced from ClinicalTrials.gov · August 10, 2026

Recruiting studies: System Lupus Erythematosus

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06675422Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabo
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT06032923Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Phase 1/Phase 2 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06182969Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)
Phase N/A · 2 location(s) · University Hospital, Montpellier · NCT05394922Allogeneic UCB-derived CAR-T for SLE
EARLY_Phase 1 · 2 location(s) · Chengdu Ucello Biotechnology Co., Ltd. · NCT07274059Wellness & Workforce Solution for Lupus/Lupus Nephritis
NA · 1 location(s) · Morehouse School of Medicine · NCT06217107Clinical Study of Cizutamig in Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · Candid Therapeutics · NCT07215663A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Phase 1 · 21 location(s) · Fate Therapeutics · NCT06308978The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Phase 2 · 19 location(s) · Children's Hospital Medical Center, Cincinnati · NCT05538208UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06920433A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · 101 location(s) · Novartis Pharmaceuticals · NCT06581198Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocy
Phase 1 · 1 location(s) · Juventas Cell Therapy Ltd. · NCT06826430Dapagliflozin in Active Lupus Nephritis
Phase 4 · 2 location(s) · Brigham and Women's Hospital · NCT07323524A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Phase 3 · 1 location(s) · Beijing Mabworks Biotech Co., Ltd. · NCT07405970An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NA · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06379646Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06946485PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Phase 4 · 27 location(s) · Aurinia Pharmaceuticals Inc. · NCT07611214Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
NA · 1 location(s) · Bioray Laboratories · NCT05988216The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Phase 4 · 1 location(s) · Ahmed Yehia Ismail · NCT07700940Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT04902807Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787MB-CART19.1 in Refractory SLE
Phase 1/Phase 2 · 3 location(s) · Miltenyi Biomedicine GmbH · NCT06189157Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
NA · 1 location(s) · Lingli Dong · NCT06277427A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (R
Phase 1 · 3 location(s) · Capstan Therapeutics · NCT06917742Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Phase N/A · 13 location(s) · University of Bern · NCT05017142Pregnancies Before the Diagnosis of Systemic Lupus Erythematosus
Phase N/A · 2 location(s) · University of Algiers · NCT07148115Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
Phase N/A · 20 location(s) · Monash University · NCT03138941Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07470151Fatigue in Lupus Intervention Programmes (FLIP)
NA · 1 location(s) · University of Edinburgh · NCT06308770
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.